Inmune Bio, Inc.   Report issue

For profit Phase 2
Founded: La Jolla CA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT03943264
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

INmune Bio | Inmune Bio, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

inkmune (2 trials)

xpro1595 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2